Advertisement
Canada markets closed
  • S&P/TSX

    22,259.16
    -31.46 (-0.14%)
     
  • S&P 500

    5,187.67
    -0.03 (-0.00%)
     
  • DOW

    39,056.39
    +172.13 (+0.44%)
     
  • CAD/USD

    0.7288
    +0.0001 (+0.02%)
     
  • CRUDE OIL

    79.22
    +0.84 (+1.07%)
     
  • Bitcoin CAD

    84,456.74
    -2,111.30 (-2.44%)
     
  • CMC Crypto 200

    1,307.04
    +12.37 (+0.96%)
     
  • GOLD FUTURES

    2,316.10
    -8.10 (-0.35%)
     
  • RUSSELL 2000

    2,055.14
    -9.51 (-0.46%)
     
  • 10-Yr Bond

    4.4920
    +0.0290 (+0.65%)
     
  • NASDAQ futures

    18,160.75
    -38.75 (-0.21%)
     
  • VOLATILITY

    13.00
    -0.23 (-1.74%)
     
  • FTSE

    8,354.05
    +40.38 (+0.49%)
     
  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     
  • CAD/EUR

    0.6777
    +0.0006 (+0.09%)
     

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024

HAYWARD, Calif., April 24, 2024--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET.

Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

ADVERTISEMENT

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240424694046/en/

Contacts

Investor Contacts:
Pulse Biosciences
Kevin Danahy, President and CEO
510.241.1077
IR@pulsebiosciences.com
or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com